Skip to content

Clinical trials

Phase 2 Papillomavirus Infections trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Papillomavirus Infections Phase: Phase 2 Country / region: United States Clear all

39 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20041
20052
20063
20071
20081
20101
20111
20122
20132
20142
20152
20161
20172
20183
20193
20202
20221
20233
20241
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed17
Recruiting6
Terminated6
Active, not recruiting4
Unknown status3
Withdrawn2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)10
GlaxoSmithKline4
Frantz Viral Therapeutics, LLC3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
Takeda2
University of Chicago2
Verrica Pharmaceuticals Inc.2
AIDS Malignancy Consortium1
Baylor College of Medicine1
Dana-Farber/Brigham and Women's Cancer Center1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Papillomavirus Infections39
Uterine Cervical Neoplasms8
Oropharyngeal Neoplasms7
Squamous Cell Carcinoma of Head and Neck7
Uterine Cervical Dysplasia6
Precancerous Conditions4
Virus Diseases4
Anus Neoplasms3
DNA Virus Infections3
Head and Neck Neoplasms3

Trials

Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.